---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-084098"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:37:36.318527+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Axsome launches SYMBRAVO for acute migraine treatment in U.S.

## Summary
- SYMBRAVO (meloxicam/rizatriptan) now available by prescription for acute migraine with or without aura in adults.
- Novel multi-mechanistic approach targeting multiple migraine pathways; rapid pain freedom at 2 hours vs placebo, sustained up to 24 hours.
- Axsome launches SYMBRAVO On My Side patient support program including savings card for eligible patients.
- SYMBRAVO uses Axsome's patented MoSEIC technology; migraine affects ~40M Americans, 63% not satisfied with current treatments.

## SEC filing metadata
- accession: 0000950170-25-084098
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/0000950170-25-084098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/axsm-20250610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-084098
- JSON: https://secwatch.observer/filing/0000950170-25-084098.json
- Plain text: https://secwatch.observer/filing/0000950170-25-084098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.